DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT

被引：609

作者：

EICHELBAUM, M

SPANNBRUCKER, N

STEINCKE, B

DENGLER, HJ

机构：

[1] Department of Medicine, University of Bonn, Bonn-Venusberg

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1979年 / 16卷 / 03期

关键词：

autosomal recessive trait; defective metabolism; pharmacogenetic defect; sparteine; sparteine-N-oxidation;

D O I：

10.1007/BF00562059

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sparteine, an antiarrhythmic and oxytocic drug, is metabolised by N1-oxidation. The sparteine-N1-oxide rearranges with loss of water to 2- and 5-dehydrosparteine. 18 (i. e., 5%) out of 360 subjects were unable to metabolise the drug. These persons, who were designated as nonmetabolisers, excreted almost 100% of the administered dose in urine as unchanged drug. The defective metabolism of sparteine was found to have a genetic basis. Sparteine-N1-oxidation appears to be determined by two allelic genes at a single locus where nonmetabolisers are homozygous for an autosomal recessive gene. © 1979 Springer-Verlag.

引用

页码：183 / 187

页数：5

共 23 条

[1]

BINNIG F, 1974, ARZNEIMITTEL-FORSCH, V24, P752

[2]

BONICKE R, 1953, ARCH EXP PATHOL PH, V220, P321

[3]

DENGLER HJ, 1977, ARZNEIMITTEL-FORSCH, V27-2, P1836

[4] INFLUENCE OF THE DEFECTIVE METABOLISM OF SPARTEINE ON ITS PHARMACOKINETICS [J].

EICHELBAUM, M ;

SPANNBRUCKER, N ;

DENGLER, HJ .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :189-194

[5]

EICHELBAUM M, 1978, BIOL OXIDATION NITRO, P113

[6]

Eichelbaum M, 1975, 6TH INT C PHARM HELS, P1071

[7]

EICHELBAUM M, 1975, ARCH PHARMACOL, V287, pR94

[8]

GOEDDE HW, 1974, INTERNIST, V15, P27

[9]

GOEDDE HW, 1967, PSEUDOCHOLINESTERASE

[10]

GOODMAN LS, 1965, PHARMACOL BASIS THER, P886

← 1 2 3 →